डासाटिनिब और निर्माट्रेल्विर और रिटोनाविर का इंटरैक्शन

Anticancer drugs abemaciclib, ceritinib, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax, vinblastine, vincristine ↑ anticancer drugs Avoid co-administration of encorafenib or ivosidenib due to potential risk of serious adverse events such as QT interval prolongation.

Avoid concomitant use of strong CYP3A4 inhibitors.

If concomitant administration of a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction [see Dosage and Administration ( 2.3 )] .

DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Dose reduction may be necessary.

Effect of Other Drugs on Dasatinib Strong CYP3A4 Inhibitors The coadministration with strong CYP3A inhibitors may increase dasatinib concentrations [see Clinical Pharmacology ( 12.3 )] .